Cenker Eken
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Cenker Eken has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
Oktay Eray
Department of Emergency Medicine, Akdeniz University Medical Faculty, Antalya, Turkey
3 shared publications- Oktay Eray
Departments of Emergency Medicine, Faculty of Medicine, Akdeniz University Hospital, Antalya, Turkey
3 shared publications - Ozlem Yigit
Department of Emergency Medicine, Faculty of Medicine, Akdeniz University, Antalya, Türkiye
3 shared publications Ayse Bacanli
2 shared publicationsBedia Gulen
2 shared publications- Can Akyol
Department of Emergency Medicine, Antalya Training and Research Hospital, Antalya, Turkey
2 shared publications
Latest Publications
- 18 December 2025
- Published by Elsevier in The Journal of Emergency Medicine
- Vol. 84, 186-187
ST-Segment Elevation in Lead aVR and Acute Intracranial Pathologies: Reconsidering the Association
- 18 December 2025
- Published by Elsevier in The Journal of Emergency Medicine
- Vol. 84, 186-187
ST-Segment Elevation in Lead aVR and Acute Intracranial Pathologies: Reconsidering the Association
- 24 July 2018
- Published by AVES YAYINCILIK A.Ş. in Balkan Medical Journal
- Vol. 35 (4) , 301-305
Intravenous Dexketoprofen versus Intravenous Paracetamol for Dysmenorrhea: A Randomized Controlled Trial
Dysmenorrhea is one of the most common acute pain disorders among women of reproductive age. To compare the effects of IV paracetamol with dexketoprofen in patients presenting with primary dysmenorrhea to the emergency department. Randomized controlled trial. Patients over 18 years old presenting with pelvic pain related to menstruation were eligible for the study. Study patients received 1 g paracetamol or 50 mg dexketoprofen in 100 mL normal saline with a 4-5 minute infusion via the intravenous route. Pain intensity was measured by a visual analog scale at 15 and 30 minutes. Patients were randomized and assigned to either of two study arms via sealed envelopes. Study drugs were identical in color, and thus both personnel and patients were blinded to the study drug. The dexketoprofen group comprised 49 patients, and the paracetamol group had 50 patients in the final analysis. The mean age of the study subjects was 20.9±2.5 and the mean duration of the pain was 1.9±1.7 (median: 1, interquartile range: 1 to 2) hours. Both dexketoprofen (median change: 33, 95% CI: 24 to 38) and paracetamol (median change: 21, 95% CI: 12 to 32) effectively reduced the pain at 15 minutes, which was repeated at 30 minutes (median change: 63, 95% CI: 57 to 65 vs 55.5, 95% CI: 50 to 59, respectively). Pain improvement in the dexketoprofen group was better than in the paracetamol group at 15 (median difference: 8, 95% CI: 0 to 16, p=0.048) and 30 (median difference: 6, 95% CI: 1 to 12, p=0.028) minutes, which was statistically significant but not clinically significant. Dexketotoprofen has a better visual analogue scale score that is not clinically relevant compared to paracetamol.
- 24 July 2018
- Published by AVES YAYINCILIK A.Ş. in Balkan Medical Journal
- Vol. 35 (4) , 301-305
Intravenous Dexketoprofen versus Intravenous Paracetamol for Dysmenorrhea: A Randomized Controlled Trial
Dysmenorrhea is one of the most common acute pain disorders among women of reproductive age. To compare the effects of IV paracetamol with dexketoprofen in patients presenting with primary dysmenorrhea to the emergency department. Randomized controlled trial. Patients over 18 years old presenting with pelvic pain related to menstruation were eligible for the study. Study patients received 1 g paracetamol or 50 mg dexketoprofen in 100 mL normal saline with a 4-5 minute infusion via the intravenous route. Pain intensity was measured by a visual analog scale at 15 and 30 minutes. Patients were randomized and assigned to either of two study arms via sealed envelopes. Study drugs were identical in color, and thus both personnel and patients were blinded to the study drug. The dexketoprofen group comprised 49 patients, and the paracetamol group had 50 patients in the final analysis. The mean age of the study subjects was 20.9±2.5 and the mean duration of the pain was 1.9±1.7 (median: 1, interquartile range: 1 to 2) hours. Both dexketoprofen (median change: 33, 95% CI: 24 to 38) and paracetamol (median change: 21, 95% CI: 12 to 32) effectively reduced the pain at 15 minutes, which was repeated at 30 minutes (median change: 63, 95% CI: 57 to 65 vs 55.5, 95% CI: 50 to 59, respectively). Pain improvement in the dexketoprofen group was better than in the paracetamol group at 15 (median difference: 8, 95% CI: 0 to 16, p=0.048) and 30 (median difference: 6, 95% CI: 1 to 12, p=0.028) minutes, which was statistically significant but not clinically significant. Dexketotoprofen has a better visual analogue scale score that is not clinically relevant compared to paracetamol.
- 1 November 2016
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 34 (11) , 2061-2064
Adropin levels and target organ damage secondary to high blood pressure in the ED
- 1 November 2016
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 34 (11) , 2061-2064
Adropin levels and target organ damage secondary to high blood pressure in the ED
- 1 September 2016
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 34 (9) , 1850-1854
The value of point-of-care ultrasound for detecting nail bed injury in ED
- 1 September 2016
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 34 (9) , 1850-1854
The value of point-of-care ultrasound for detecting nail bed injury in ED
- 1 August 2016
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 34 (8) , 1458-1461
Ketoprofen gel improves low back pain in addition to IV dexketoprofen: a randomized placebo-controlled trial
- 1 August 2016
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 34 (8) , 1458-1461
Ketoprofen gel improves low back pain in addition to IV dexketoprofen: a randomized placebo-controlled trial
- 11 May 2016
- Published by Wiley in Academic Emergency Medicine
- Vol. 23 (6) , 674-678
Comparison of Intravenous Morphine Versus Paracetamol in Sciatica: A Randomized Placebo Controlled Trial
The objective was to compare intravenous morphine and intravenous acetaminophen (paracetamol) for pain treatment in patients presenting to the emergency department with sciatica. Patients, between the ages of 21 and 65 years, suffering from pain in the sciatic nerve distribution and a positive straight leg-raise test composed the study population. Study patients were assigned to one of three intravenous interventions: morphine (0.1 mg/kg), acetaminophen (1 g), or placebo. Physicians, nurses, and patients were blinded to the study drug. Changes in pain intensity were measured at 15 and 30 minutes using a visual analog scale. Rescue drug (fentanyl) use and adverse effects were also recorded. Three-hundred patients were randomized. The median change in pain intensity between treatment arms at 30 minutes were as follows: morphine versus acetaminophen 25 mm (95% confidence interval [CI] = 20 to 29 mm), morphine versus placebo 41 mm (95% CI = 37 to 45 mm), and acetaminophen versus placebo 16 mm (95% CI = 12 to 20 mm). Eighty percent of the patients in the placebo group (95% CI = 63.0% to 99%), 18% of the patients in the acetaminophen group (95% CI = 10.7% to 28.5%), and 6% of those in the morphine group (95% CI = 2.0% to 13.2%) required a rescue drug. Adverse effects were similar between the morphine and acetaminophen groups. Morphine and acetaminophen are both effective for treating sciatica at 30 minutes. However, morphine is superior to acetaminophen.
- 11 May 2016
- Published by Wiley in Academic Emergency Medicine
- Vol. 23 (6) , 674-678
Comparison of Intravenous Morphine Versus Paracetamol in Sciatica: A Randomized Placebo Controlled Trial
The objective was to compare intravenous morphine and intravenous acetaminophen (paracetamol) for pain treatment in patients presenting to the emergency department with sciatica. Patients, between the ages of 21 and 65 years, suffering from pain in the sciatic nerve distribution and a positive straight leg-raise test composed the study population. Study patients were assigned to one of three intravenous interventions: morphine (0.1 mg/kg), acetaminophen (1 g), or placebo. Physicians, nurses, and patients were blinded to the study drug. Changes in pain intensity were measured at 15 and 30 minutes using a visual analog scale. Rescue drug (fentanyl) use and adverse effects were also recorded. Three-hundred patients were randomized. The median change in pain intensity between treatment arms at 30 minutes were as follows: morphine versus acetaminophen 25 mm (95% confidence interval [CI] = 20 to 29 mm), morphine versus placebo 41 mm (95% CI = 37 to 45 mm), and acetaminophen versus placebo 16 mm (95% CI = 12 to 20 mm). Eighty percent of the patients in the placebo group (95% CI = 63.0% to 99%), 18% of the patients in the acetaminophen group (95% CI = 10.7% to 28.5%), and 6% of those in the morphine group (95% CI = 2.0% to 13.2%) required a rescue drug. Adverse effects were similar between the morphine and acetaminophen groups. Morphine and acetaminophen are both effective for treating sciatica at 30 minutes. However, morphine is superior to acetaminophen.
- 1 May 2016
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 34 (5) , 866-870
Point-of-care ultrasonography for the management of shoulder dislocation in ED
- 1 May 2016
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 34 (5) , 866-870
Point-of-care ultrasonography for the management of shoulder dislocation in ED
- 1 August 2015
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 33 (8) , 1042-1044
Prognosis of Critically Ill Patients in the ED and Value of Perfusion Index Measurement: A Cross-Sectional Study
- 1 August 2015
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 33 (8) , 1042-1044
Prognosis of Critically Ill Patients in the ED and Value of Perfusion Index Measurement: A Cross-Sectional Study
- 1 July 2015
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 33 (7) , 904-906
Ketamine may be related to minor troponin elevations in children undergoing minor procedures in the ED
- 1 July 2015
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 33 (7) , 904-906
Ketamine may be related to minor troponin elevations in children undergoing minor procedures in the ED
- 5 May 2015
- Published by SAGE Publications in Cephalalgia
- Vol. 36 (2) , 179-184
Intravenous dexketoprofen vs placebo for migraine attack in the emergency department: A randomized, placebo-controlled trial
Migraine is a leading headache etiology that frequently presents to the emergency department (ED). In the present study, we aimed to determine the efficacy of dexketoprofen in aborting migraine headaches in the ED. This prospective, randomized, double-blind study was conducted in an ED of a tertiary care hospital using allocation concealment. Patients were allocated into two arms to receive the study drug; 50 mg dexketoprofen in 50 ml saline and 50 ml saline as placebo. Change in pain intensity was measured by the visual analog scale at baseline, both at 30 and 45 minutes after the study medication was administered. Rescue medication requirement and pain relapse were also recorded by a telephone follow-up at 48 hours. A total of 224 patients (112 in each group) were included into the final analysis. Mean age of the study participants was 37 ± 11 (SD) and 25% (n = 56) of them were male. The median pain improvement at 45 minutes for patients receiving dexketoprofen was 55 (IQR: 49 to 60) and 30 (IQR: 25 to 35) for those receiving placebo. The mean difference between the two groups at 45 minutes was 21.4 (95% CI: 14.4. to 28.5). Rescue drugs were needed in 22.3% of patients who received dexketoprofen compared to 55.4% in patients who received placebo (dif: 33.1%; 95% CI: 20% to 45%). There were no adverse events reported in either group during the study period. Intravenous dexketoprofen is superior to placebo in relieving migraine headaches in the ED. It may be a suitable therapy with minimum side effects in patients presenting with a migraine headache to the ED.
- 5 May 2015
- Published by SAGE Publications in Cephalalgia
- Vol. 36 (2) , 179-184
Intravenous dexketoprofen vs placebo for migraine attack in the emergency department: A randomized, placebo-controlled trial
Migraine is a leading headache etiology that frequently presents to the emergency department (ED). In the present study, we aimed to determine the efficacy of dexketoprofen in aborting migraine headaches in the ED. This prospective, randomized, double-blind study was conducted in an ED of a tertiary care hospital using allocation concealment. Patients were allocated into two arms to receive the study drug; 50 mg dexketoprofen in 50 ml saline and 50 ml saline as placebo. Change in pain intensity was measured by the visual analog scale at baseline, both at 30 and 45 minutes after the study medication was administered. Rescue medication requirement and pain relapse were also recorded by a telephone follow-up at 48 hours. A total of 224 patients (112 in each group) were included into the final analysis. Mean age of the study participants was 37 ± 11 (SD) and 25% (n = 56) of them were male. The median pain improvement at 45 minutes for patients receiving dexketoprofen was 55 (IQR: 49 to 60) and 30 (IQR: 25 to 35) for those receiving placebo. The mean difference between the two groups at 45 minutes was 21.4 (95% CI: 14.4. to 28.5). Rescue drugs were needed in 22.3% of patients who received dexketoprofen compared to 55.4% in patients who received placebo (dif: 33.1%; 95% CI: 20% to 45%). There were no adverse events reported in either group during the study period. Intravenous dexketoprofen is superior to placebo in relieving migraine headaches in the ED. It may be a suitable therapy with minimum side effects in patients presenting with a migraine headache to the ED.